

FIG. 1

BINDING




FIG. 2A

BINDING INHIBITION




FIG. 2B

0976781.020601




FIG. 2C




FIG. 2D

0976781.020601




FIG. 3A




FIG. 3B





FIG. 3C



(125-PRO) IL-2 (mM)

FIG. 4A

(125-PRO) IL-2 (mM)

FIG. 4B

IL-9 (u/ml)

FIG. 4C




FIG. 4D




FIG. 4E




FIG. 4F




FIG. 5A




FIG. 5B




FIG. 5C

INTERLEUKINE-2 RECEPTOR




FIG. 6A

IL-2 AND IP 130 SEQUENCE (α -HELICES ARE BOXED)




FIG. 6B

Figure 1 is a graph showing the effect of IL-2 concentration on $[^3\text{H}]$ TdR incorporation and IP130 levels. The x-axis represents IL-2 concentration in nM on a logarithmic scale, with major ticks at 1, 10, and 100. The left y-axis represents $[^3\text{H}]$ TdR INCORPORATION ($\times 10^{-3}$) from 0 to 100. The right y-axis represents IP130 (μM) from 0 to 100. A dashed vertical line is drawn at IL-2 = 1 nM. The data points for $[^3\text{H}]$ TdR incorporation (open circles) show a peak at 1 nM IL-2 and then a decrease. The data points for IP130 (filled circles) show a sharp increase starting around 10 nM IL-2.

IL-2 (nM)	$[^3\text{H}]$ TdR INCORPORATION ($\times 10^{-3}$)	IP130 (μM)
1	~90	~0
2	~85	~0
3	~80	~0
5	~75	~0
10	~65	~0
20	~55	~0
50	~45	~10
100	~40	~20

IP130 (μM)	[3H] TdR INCORPORATION (x10 ⁻³)
0	0.1
2.5	0.2
5	0.3
10	0.5
25	1.0
50	6.5
100	5.5




FIG. 8A




FIG. 8B




FIG. 8C




FIG. 8D




FIG. 9A




FIG. 9B




FIG. 9C





FIG. 9E

FIG. 9D


1	10	20	30		% HELIX (CIRCULAR DICHROISM)	MAIN MOLECULAR SPECIES	ACTIVITY
APTSSSTKTQLQLEHLLDLQMLNGINN							
1			30		50% (150 @ 30 μ M) 35% (4 μ M)	TETRAMER (4M-8M, K _d =30-100 μ M) /OCTAMER	+++
	10		30		22% (150 @ 30 μ M)	DIMER (1M-2M, K _d =0.2 μ M) /TETRAMER (2M-4M, K _d =100 μ M)	++
1					<2%		-
1	10				0%	DIMER (1M-2M, K _d =50 μ M) (2M-4M, K _d =1.4mM)	-
	5	15			0%	DIMER (1M-2M, K _d =113 μ M)	-
	10	20			0%	MONOMER	ND
		20	20		<5%	MONOMER	+

FIG. 10



IP130

FIG. 11A




IL-2R β

IL-2R β

IP130

FIG. 11B






F I G . 1 2 B

NO STIMULATION
IL - 2
IP 130
IL - 2 + IP 130

FIG. 13



▲ ACTIVATED STATs



IL-2 RECEPTOR AND ITS MAJOR SIGNAL TRANSDUCTION PATHWAY

FIG. 14

NK CELLS (CD56⁺) ENTERING IN S+G2/M PHASES AFTER IP130 STIMULATION
(SYNERGY WITH IL-2)

TREATMENT			J31	J32	J33
IL-2 50 nM			14	12	14
	IP130	60 μ M	0	17	≤ 5
	IP130	120 μ M	0	14	< 5
IL-2 50 nM +	IP130	60 μ M	26	21	7
IL-2 50 nM +	IP130	120 μ M	28	28	28

FIG. 15

0976781.020601




FIG. 16B

FIG. 16A




FIG. 16C

FIG. 16D




FIG. 16F




FIG. 16E




FIGURE 17




FIGURE 18

09776781 020604




FIGURE 19